Novartis : Solid performance in Q3. Sandoz enters strategic review
>Good work at the operating level. All options open for Sandoz - The company's Q3 2021 figures were in line with expectations for sales but 3.6% higher at the core EPS level. Sales were up 5% cc and benefited from a favourable currency effect of +1% over the period. More specifically, pharma sales grew by 7% cc. Cosentyx and Entresto reached $ 1,247m and $ 1,174m respectively, +6% and 3% above expectations. Sales of the two products were driven by both China and ...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.